Press Releases

Date Title
03/29/16
Summary ToggleNeothetics Reports Fourth Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , March 29, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today reported financial results and business progress for the fourth quarter 2015. Fourth Quarter 2015 Highlights Neothetics reported top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials
03/28/16
Summary ToggleNeothetics Provides Update and Plan Forward for LIPO-202 Program Printer Friendly Version SAN DIEGO , March 28, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided an update and plan forward for its LIPO-202 program. Neothetics plans to initiate a Phase 2 trial with a modified formulation of LIPO-202 in the third quarter of 2016 for the reduction of central abdominal
02/18/16
Summary ToggleNeothetics Announces Leadership Change and Preliminary Update on LIPO-202 Printer Friendly Version Company Reports Preliminary Fourth Quarter 2015 Cash and Cash Equivalents of Approximately $37.7 Million as of December 31, 2015 SAN DIEGO , Feb. 18, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic
12/14/15
Summary ToggleNeothetics Reports LIPO-202 Top-Line Phase 3 Trial Results for the Reduction of Central Abdominal Bulging Printer Friendly Version SAN DIEGO , Dec. 14, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat.
12/07/15
Summary ToggleNeothetics Announces Issuance by USPTO of Fourth Patent Directed to LIPO-202 Lead Clinical Asset Printer Friendly Version SAN DIEGO , Dec. 7, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent Number 9,198,885 by the United States Patent and Trademark Office (USPTO).
12/01/15
Summary ToggleNeothetics Tightens Guidance for Timing of Top-Line Pivotal Phase 3 Data Printer Friendly Version SAN DIEGO , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today tightened its guidance regarding the timing of release of top-line data for its two pivotal U.S.
11/24/15
Summary ToggleNeothetics to Present in the 27th Annual Piper Jaffray Healthcare Conference Printer Friendly Version SAN DIEGO , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today the company plans to participate in the 27th Annual Piper Jaffray Healthcare Conference in New York, NY .
11/12/15
Summary ToggleNeothetics Reports Third Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , Nov. 12, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the third quarter 2015.
11/05/15
Summary ToggleNeothetics to Release Third Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , Nov. 05, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its third quarter 2015 financial results before the market opens on Thursday,
10/06/15
Summary ToggleNeothetics Announces Issuance by USPTO of Additional Patent Directed to LIPO-202 Lead Clinical Asset Printer Friendly Version SAN DIEGO , Oct. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent No. 9,132,084 by the United States Patent and Trademark Office (USPTO).